- Home
- CAPR vs JELD Comparison
CAPR vs JELD Comparison
Compare CAPR & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- JELD
- Stock Information
- Founded
- CAPR 2005
- JELD 1960
- Country
- CAPR United States
- JELD United States
- Employees
- CAPR N/A
- JELD N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- JELD Forest Products
- Sector
- CAPR Health Care
- JELD Basic Materials
- Exchange
- CAPR Nasdaq
- JELD Nasdaq
- Market Cap
- CAPR 322.7M
- JELD 383.8M
- IPO Year
- CAPR N/A
- JELD 2017
- Fundamental
- Price
- CAPR $8.43
- JELD $4.78
- Analyst Decision
- CAPR Strong Buy
- JELD Hold
- Analyst Count
- CAPR 8
- JELD 8
- Target Price
- CAPR $24.75
- JELD $7.34
- AVG Volume (30 Days)
- CAPR 2.7M
- JELD 1.4M
- Earning Date
- CAPR 08-06-2025
- JELD 08-05-2025
- Dividend Yield
- CAPR N/A
- JELD N/A
- EPS Growth
- CAPR N/A
- JELD N/A
- EPS
- CAPR N/A
- JELD N/A
- Revenue
- CAPR $17,363,588.00
- JELD $3,592,472,000.00
- Revenue This Year
- CAPR $453.92
- JELD N/A
- Revenue Next Year
- CAPR N/A
- JELD $3.40
- P/E Ratio
- CAPR N/A
- JELD N/A
- Revenue Growth
- CAPR N/A
- JELD N/A
- 52 Week Low
- CAPR $3.52
- JELD $3.27
- 52 Week High
- CAPR $23.40
- JELD $17.70
- Technical
- Relative Strength Index (RSI)
- CAPR 38.63
- JELD 59.13
- Support Level
- CAPR $6.26
- JELD $4.93
- Resistance Level
- CAPR $7.28
- JELD $5.25
- Average True Range (ATR)
- CAPR 0.69
- JELD 0.25
- MACD
- CAPR -0.04
- JELD 0.06
- Stochastic Oscillator
- CAPR 10.28
- JELD 66.52
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.